LGND LIGAND PHARMACEUTICALS INC
Pharmaceutical Preparations · Nasdaq · SEC CIK 886163 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY1.0%
TTM net income YoY5.9%
TTM EPS YoY9.7%
Revenue 3-yr CAGR18.2%
Net income 3-yr CAGR46.2%
Margins
Gross margin—
Operating margin9.5%
Net margin20.3%
FCF margin35.7%
EBITDA margin23.2%
Returns
ROE5.4%
ROA2.8%
ROIC (approx.)1.4%
Asset turnover0.14x
Leverage & solvency
Liabilities / assets57.0%
Debt / equity1.17x
Current ratio1.22x
Interest coverage2.94x
Cash quality & payout
Operating cash flow / net income1.77x
Accruals ratio-2.1%
Payout ratio—
Capex / revenue0.2%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $78.75M | $63.69M | $51.72M | $59.67M | $115.46M | $47.63M | $45.33M | $42.81M |
| R&D expense | $2.77M | $14.67M | $2.15M | $3.51M | $21.02M | $6.57M | $50.09M | $4.42M |
| SG&A expense | $72.62M | $29.12M | $20.84M | $25.03M | $28.45M | $20.18M | $18.80M | $25.61M |
| Operating income | -$15.76M | $8.59M | $17.37M | $13.84M | $55.39M | $8.44M | -$36.22M | -$9.64M |
| Interest expense | $2.90M | $1.75M | $1.75M | $1.78M | $910,000 | $1.15M | $867,000 | $883,000 |
| Pretax income | -$44.09M | $64.30M | -$24.26M | $56.78M | $141.14M | $11.22M | -$50.18M | -$39.20M |
| Income tax | -$15.61M | $15.80M | -$10.91M | $12.00M | $23.86M | $6.38M | -$7.73M | -$8.11M |
| Net income | -$28.48M | $48.51M | -$13.35M | $44.78M | $117.27M | $4.85M | -$42.45M | -$31.09M |
| EBITDA | -$5.43M | $16.81M | $25.58M | $22.06M | $63.66M | $16.97M | -$27.45M | -$1.01M |
| EPS (basic) | -1.43 | 2.42 | -0.67 | — | 5.99 | 0.25 | -2.21 | — |
| EPS (diluted) | -1.43 | 2.22 | -0.67 | — | 5.68 | 0.24 | -2.21 | — |
| Weighted avg. shares (diluted) | 19.96M | 21.84M | 19.88M | — | 20.63M | 19.93M | 19.19M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $55.96M | $1.01B | $115.08M | $174.93M | $139.38M | $67.67M | $47.99M | $72.31M |
| Short-term investments | $391.44M | $351.06M | $664.33M | $558.59M | $525.15M | $177.35M | $160.91M | $183.86M |
| Receivables | $83.22M | $67.01M | $53.38M | $59.60M | $57.56M | $41.29M | $38.49M | $38.38M |
| Inventory | $14.51M | $10.26M | $13.27M | $9.13M | $11.90M | $15.49M | $14.61M | $14.11M |
| Current assets | $608.23M | $1.46B | $865.41M | $832.27M | $753.92M | $352.94M | $309.32M | $331.56M |
| PP&E, net | $3.71M | $3.40M | $3.44M | $3.57M | $3.47M | $3.63M | $3.62M | $15.13M |
| Goodwill | $207.86M | $101.54M | $101.54M | $101.54M | $101.54M | $101.54M | $101.54M | $105.25M |
| Intangibles | $302.04M | $209.24M | $217.34M | $225.44M | $233.53M | $250.13M | $258.39M | $266.65M |
| Total assets | $2.24B | $2.19B | $1.53B | $1.56B | $1.48B | $948.60M | $905.43M | $941.77M |
| Current liabilities | $500.57M | $46.74M | $40.67M | $37.45M | $30.54M | $64.73M | $58.68M | $37.11M |
| Short-term debt | $448.31M | — | — | — | — | — | — | — |
| Long-term debt | $679.91M | $1.13B | $446.90M | $446.19M | $445.49M | — | — | $0 |
| Total debt | $1.13B | $1.13B | $446.90M | $446.19M | $445.49M | — | — | $0 |
| Total liabilities | $1.28B | $1.22B | $534.78M | $543.42M | $526.60M | $120.08M | $109.90M | $111.33M |
| Shareholders' equity | $961.76M | $967.52M | $997.32M | $1.02B | $950.17M | $827.31M | $795.59M | $830.44M |
| Net debt | $1.07B | $119.89M | $331.82M | $271.26M | $306.12M | — | — | -$72.31M |
| Shares outstanding | 20.00M | 19.92M | 20.03M | 19.77M | 19.66M | 19.41M | 19.28M | 19.11M |
| Cash flow statement | ||||||||
| Operating cash flow | -$27.59M | $24.02M | $48.69M | $45.91M | $13.09M | $15.80M | -$25.45M | $28.47M |
| Capital expenditure | $142,000 | $26,000 | $228,000 | $9,000 | $15,000 | $214,000 | $214,000 | $712,000 |
| Free cash flow | -$27.73M | $23.99M | $48.46M | $45.91M | $13.07M | $15.59M | -$25.66M | $27.76M |
| Investing cash flow | -$877.99M | $321.12M | -$94.35M | -$18.10M | -$353.44M | -$10.67M | $4.89M | -$38.62M |
| Financing cash flow | $4.06M | $546.43M | -$14.13M | $8.33M | $409.64M | $14.99M | -$4.75M | $20.39M |
| Depreciation & amortization | $10.32M | $8.21M | $8.22M | $8.21M | $8.27M | $8.52M | $8.77M | $8.63M |
| Stock-based compensation | $18.18M | $13.65M | $10.60M | $14.27M | $14.75M | $10.00M | $7.84M | $7.52M |
| Share buybacks | $0 | — | — | $0 | $15.00M | — | — | $0 |
Free plan shows the latest 8 periods; Pro shows all 66 🔒
· This company does not report gross profit in XBRL.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.